Cancer chemotherapy and immune regulation

American Journal of Immunology

Volumn 5, Issue 1, 2009, Pages 8-16

  Barrett, John ^a   Le Blanc, Katarina ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer chemotherapy; Immune recovery; Immunosurveillance

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BORTEZOMIB; CD3 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IMATINIB; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PENTOSTATIN; TIOGUANINE; TUMOR ANTIGEN; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; CANCER RECURRENCE; CANCER SUSCEPTIBILITY; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LEUKEMIA; LUPUS VULGARIS; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; TREATMENT OUTCOME; TUMOR IMMUNITY;

EID: 70249110454     PISSN: 1553619X     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajisp.2009.8.16     Document Type: Review

References (74)

1. Burnet, F.M., 1970. The concept of immunological surveillance. Prog. Exp. Tumor Res., 13: 1-27. http://www.ncbi.nlm.nih.gov/pubmed/4921480
2. Dunn, G.P., L.J. Old and R.D. Schreiber, 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol., 22: 329-360. http://www.ncbi.nlm.nih.gov/pubmed/15032581
3. Filipovich, A.H., A. Mathur, D. Kamat, J.H. Kersey and R.S. Shapiro, 1994. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency, 5: 91-112. http://www.ncbi.nlm.nih.gov/pubmed/8032367
4. Swann, J.B. and M.J. Smyth, 2007. Immune surveillance of tumors. J. Clin. Invest., 117: 1137-1146. DOI: 10.1172/JCI31405
5. Smyth, M.J., G.P. Dunn and R.D. Schreiber, 2006. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol., 90: 1-50. http://www.ncbi.nlm.nih.gov/pubmed/16730260
6. Koebel, C.M., W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig and L.J. Old et al., 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450: 903-907. http://www.ncbi.nlm.nih.gov/ pubmed/18026089
7. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky and B. Mlecnik et al., 2006. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313: 1960-1964. http://www.ncbi.nlm.nih.gov/pubmed/17008531
8. Ohtani, H., 2007. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immunol., 7: 1-10. http://www.cancerimmunity.org/v7p10/070610.pdf
9. Sato, E., S.H. Olson, J. Ahn and B. Bundy, H. Nishikawa and F. Qian et al., 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA., 102: 18538-18543. http://www.pnas.org/content/102/51/18538/suppl/DC1?ck=nck
10. Franklin, J., H. Tesch, M.L. Hansmann and V. Diehl, 1998. Lymphocyte predominant Hodgkin's disease: pathology and clinical implication. Ann. Oncol., 9: S39-S44. http://www.ncbi.nlm.nih.gov/pubmed/9926236
11. El, W.A., S. Akhtar, W.A. Mourad, D. Ajarim and M. Abdelsalm et al., 2007. T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: Report on 61 patients and review of literature. Leuk Lymphoma, 48: 1764-1773. http://www.ncbi.nlm.nih.gov/pubmed/17786712
12. Street, S.E., Y. Hayakawa, Y. Zhan, A.M. Lew and D. MacGregor et al., 2004. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med., 199: 879-884. http://www.ncbi.nlm.nih.gov/pubmed/15007091
13. Palmer, S., C.A. Hanson, C.S. Zent, L.F. Porrata and B. Laplant et al., 2008. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br. J. Haematol., 141: 607-614. http://www.ncbi.nlm.nih.gov/pubmed/ 18384436
14. Savani, B.N., S. Goodman and A.J. Barrett, 2009. Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin. Cancer Res., 15: 2219-2221. http://www.ncbi.nlm.nih.gov/pubmed/19293253
15. Dolcetti, R., 2007. B lymphocytes and Epstein-Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmun. Rev., 7: 96-101. http://www.ncbi.nlm.nih.gov/pubmed/18035317
16. Gottschalk, S., H.E. Heslop and C.M. Rooney, 2005. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma, 46: 1-10. http://www.ncbi.nlm.nih.gov/pubmed/15621775
17. Barrett, A.J., 2008. Understanding and harnessing the graft-versus-leukaemia effect. Br. J. Haematol., 142: 877-888. http://www.ncbi.nlm.nih.gov/pubmed/18564358
18. Farag, S.S., T.A. Fehniger, L. Ruggeri, A. Velardi and M.A. Caligiuri, 2002. Natural killer cell receptors: New biology and insights into the graft-versus leukemia effect. Blood, 100: 1935-1947. http://www.ncbi.nlm.nih.gov/pubmed/12200350
19. Ioannides, C.G. and T.L. Whiteside, 1993. T cell recognition of human tumors: Implications for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol., 66: 91-106. http://www.ncbi.nlm.nih.gov/pubmed/ 8453790
20. Gannage, M., M. Abel, A.S. Michallet, S. Delluc and M. Lambert et al., 2005. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and adoptive cellular immunotherapy. J. Immunol., 174: 8210-8218. http://www.jimmunol.org/cgi/ content/abstract/174/12/8210
21. Barrett, A.J. and K. Rezvani, 2007. Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin. Exp. Immunol., 148: 189-198. http://www.ncbi.nlm.nih.gov/pubmed/17437417
22. Molldrem, J.J., P.P. Lee, C. Wang, K. Felio and H.M. Kantarjian et al., 2000. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med., 6: 1018-1023. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd= ShowDetailView&TermToSearch=10973322
23. Mustjoki, S., T. Lundan, S. Knuutila and K. Porkka, 2007. Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. Leukemia, 21: 2363-2368. http://www.ncbi.nlm.nih.gov/pubmed/17568811
24. Sloand, E.M., C.O. Wu, P. Greenberg, N. Young and J. Barrett, 2008. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J. Clin. Oncol., 26: 2505-2511. http://www.ncbi.nlm.nih.gov/pubmed/18413642
25. Barrett, A.J. and E.M. Sloand, 2009. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica, 94: 449-451. http://www.ncbi.nlm.nih.gov/ pubmed/19336747
26. Brodsky, R.A., 2002. High dose cyclophosphamide treatment for autoimmune disorders. ScientificWorldJournal, 2: 1808-1815. http://www.ncbi.nlm.nih.gov/pubmed/12806171
27. Genestier, L., R. Paillot, S. Fournel, C. Ferraro, P. Miossec and J.P. Revillard, 1998. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest., 102: 322-328. http://cat.inist.fr/?aModele=afficheN&cpsidt=10513615
28. Ferraro, C., L. Quemeneur, A.F. Prigent, C. Taverne, J.P. Revillard and N. Bonnefoy-Berard, 2000. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells. Cancer Res., 60: 1901-1907. http://cancerres.aacrjournals.org/cgi/content/abstract/60/7/1901
29. Robak, T., E. Lech-Maranda, A. Korycka and E. Robak, 2006. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: Mechanism of action and clinical activity. Curr. Med. Chem., 13: 3165-3189. http://www.ncbi.nlm.nih.gov/pubmed/17168705
30. Löwenberg, M., C. Stahn, D.W. Hommes and F. Buttgereit, 2008. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids, 73: 1025-1029. http://www.ncbi.nlm.nih.gov/pubmed/18221974
31. Machiels, J.P., R.T. Reilly, L.A. Emens, A.M. Ercolini and R.Y. Lei et al., 2001. Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res., 61: 3689-3697. http://www.ncbi.nlm.nih.gov/pubmed/ 11325840
32. Zhu, D., L.G. Corral, Y.W. Fleming and B. Stein, 2008. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother., 57:1849-1859. DOI: 10.1007/s00262-008-0512-7
33. Lundqvist, A., S.I. Abrams, D.S. Schrump, G. Alvarez and D. Suffredini et al., 2006. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res., 66: 7317-7325. http://cat.inist.fr/?aModele=afficheN&cpsidt=17981442
34. Yong, A.S., K. Keyvanfar, N. Hensel, R. Eniafe and B.N. Savani et al., 2009. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood, 113: 875-882. http://www.ncbi.nlm.nih.gov/pubmed/18922853
35. Seggewiss, R., D.A. Price and M.A. Purbhoo, 2008. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: An update. Cytotherapy, 10: 633-641. DOI: 10.1080/14653240802317639
36. Ménard, C., F. Martin, L. Apetoh, F. Bouyer and F. Ghiringhelli, 2008. Cancer chemotherapy: Not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol. Immunother., 57: 1579-1587. http://www.ncbi.nlm.nih.gov/pubmed/18369619
37. Suzuki, E., V. Kapoor, A.S. Jassar, L.R. Kaiser and S.M. Albelda, 2005. Gemcitabine selectively eliminates splenic Gr-1 +/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res., 11: 6713-6721. http://clincancerres.aacrjournals.org/cgi/content/abstract/11/18/6713
38. Galustian, C., B. Meyer, M.C. Labarthe, K. Dredge and D. Klaschka et al., 2008. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother., 58: 1033-1045. http://www.ncbi.nlm.nih.gov/pubmed/ 19009291
39. Salem, M.L., C.M. Díaz-Montero, A.A. Al-Khami and S.A. El-Naggar et al., 2009. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly (I:C). J. Immunol., 182: 2030-2040. http://www.ncbi.nlm.nih.gov/pubmed/19201856
40. Baxevanis, C.N., S.A. Perez and M. Papamichail, 2009. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother., 58: 317-324. http://cat.inist.fr/?aModele=afficheN&cpsidt=21174187
41. Gasser, S., S. Orsulic, E.J. Brown and D.H. Raulet, 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature, 436: 1186-1190. DOI: 10.1038/nature03884
42. Lacour, S., A. Hammann, A. Wotawa, L. Corcos and E. Solary, 2001. Dimanche-Boitrel MT Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res., 61: 1645-1651. http://www.ncbi.nlm.nih.gov/pubmed/11245478
43. Micheau, O., E. Solary, A. Hammann, F. Martin and M.T. Dimanche-Boitrel, 1997. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J. Natl. Cancer Inst., 89: 783-789. http://www.ncbi.nlm.nih.gov/pubmed/9182976
44. Mackall, C.L., 2000. T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review. Stem Cells, 18: 10-18. http://www.ncbi.nlm.nih.gov/pubmed/10661568
45. Williams, K.M., F.T. Hakim and R.E. Gress, 2007. T cell immune reconstitution following lymphodepletion. Semin Immunol., 19: 318-330. http://www.ncbi.nlm.nih.gov/pubmed/18023361
46. Dudley, M.E., J.R. Wunderlich, P.F. Robbins, J.C. Yang and P. Hwu et al., 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298: 850-854. http://www.ncbi.nlm.nih.gov/pubmed/12242449
47. Paulos, C.M., A. Kaiser, Wrzesinski, C.S. Hinrichs and L. Cassard et al., 2007. Toll-like receptors in tumor immunotherapy. Clin. Cancer Res., 13: 5280-5280. DOI: 10.1158/1078-0432.CCR-07-1378
48. Savani, B.N., S. Mielke, S. Adams, M. Uribe and K. Rezvani et al., 2007. Rapid natural killer cell recovery determines outcome after T-cell depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia, 21: 2145-2152. http://www.nature.com/leu/journal/v21/ n10/full/2404892a.html
49. Storek, J., M. Geddes, F. Khan, B. Huard and C. Helg et al., 2008. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol. 30: 425-437. http://www.ncbi.nlm.nih.gov/pubmed/18949477
50. Mackall, C.L., T.A. Fleisher, M.R. Brown, M.P. Andrich and C.C. Chen et al., 1997. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood, 89: 3700-3707. http://www.ncbi.nlm.nih.gov/pubmed/9160675
51. Bruserud, O., E. Ulvestad, S. Berentsen, J. Bergheim and I. Nesthus, 1998. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: Characterization of clonogenic T-cell proliferation. Scand J. Immunol., 47: 54-62. http://www.ncbi.nlm.nih.gov/ pubmed/9467659
52. Wendelbo, Ø., I. Nesthus, M. Sjo, K. Paulsen, P. Ernst and Ø. Bruserud, 2004. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol. Immunother., 53: 740-747. http://www.ncbi.nlm.nih.gov/pubmed/15133630
53. Powles, R., S. Singhal, J. Treleaven, S. Kulkarni and C. Horton, 1998. Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood, 91: 3481-3486. http://www.ncbi.nlm.nih.gov/ pubmed/9558408
54. Chakrabarti, S., J. Brown, M. Guttridge, D.H. Pamphilon, A. Lankester and D.I. Marks, 2003. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback. Bone Marrow Transplant., 32: 23-30. http://www.ncbi.nlm.nih.gov/pubmed/12815474
55. Kim, D.H., J.G. Kim, S.K. Sohn, W.J. Sung and J.S. Suh et al., 2004. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br. J. Haematol., 125: 217-224. http://www.ncbi.nlm.nih.gov/pubmed/15059145
56. Kumar, S., M.G. Chen, D.A. Gastineau, M.A. Gertz and D.J. Inwards et al., 2001. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant., 28: 951-956. http://www.ncbi.nlm.nih.gov/pubmed/ 11753550?dopt=Abstract
57. Lee, K.H., S.J. Choi, J.H. Lee, J.S. Lee, W.K. Kim and K.B. Lee et al., 2005. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica, 90: 939-948. http://cat.inist.fr/ ?aModele=afficheN&cpsidt=16955657
58. Savani, B.N., K. Rezvani, S. Mielke, A. Montero and R. Kurlander et al., 2006. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 107: 1688-1695. DOI: 10.1182/ blood-2005-05-1897
59. Savani, B.N., S. Mielke, K. Rezvani, A. Montero and A.S. Yong et al., 2007. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant., 13: 1216-1223. http://www.ncbi.nlm.nih.gov/pubmed/17889359
60. Le Blanc, K., A.J. Barrett, M. Schaffer, H. Hägglund, P. Ljungman and M. Remberger, 2009. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myeloid malignancies. Biol. Blood Marrow Transplant., 15: 12-13. DOI: 10.1016/j.bbmt.2008.12.036
61. Hiwase, D.K., S. Hiwase, M. Bailey, G. Bollard and A.P. Schwarer, 2008. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy, 10: 507-501. http://www.ncbi.nlm.nih.gov/pubmed/18608354
62. Porrata, L.F., M.A. Gertz, D.J. Inwards and M.R. Litzow et al., 2001. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood, 98: 579-585. http://cat.inist.fr/ ?aModele=afficheN&cpsidt=1052912
63. Porrata, L.F., D.J. Inwards, S.M. Ansell, I.N. Micallef and P.B. Johnston et al., 2008. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: A prospective study. Biol. Blood Marrow Transplant., 14: 807-816. DOI: 10.1016/j.bbmt.2008.04.013
64. Porrata, L.F., D.J. Inwards, I.N. Micallef, S.M. Ansell, S.M. Geyer and S.N. Markovic, 2002. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br. J. Haematol., 117: 629-633. http://www.ncbi.nlm.nih.gov/pubmed/12028034
65. Porrata, L.F., M.R. Litzow, A. Tefferi, L. Letendre, S. Kumar and S.M. Geyer et al., 2002. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia, 16: 1311-1318. http://www.nature.com/leu/journal/v16/n7/full/2402503a.html
66. Behl, D., L.F. Porrata, S.N. Markovic, L. Letendre, R.K. Pruthi and C.C. Hook et al., 2006. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia, 20: 29-34. http://www.ncbi.nlm.nih.gov/pubmed/ 16281063
67. De Angulo, G., C. Yuen, S.L. Palla, P.M. Anderson and P.A. Zweidler-McKay, 2008. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: Implications for risk stratification and future studies. Cancer, 112: 407-415. http://www.ncbi.nlm.nih.gov/pubmed/ 18058809
68. Lowdell, M.W., R. Craston, D. Samuel, M.E. Wood, E. O'Neill and V. Saha et al., 2002. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br. J. Haematol., 117: 821-827. http://www.ncbi.nlm.nih.gov/ pubmed/12060116
69. Rosenberg, S.A. and M.E. Dudley, 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21:233-40.
70. Gress, R.E., K.V. Komanduri, H. Einsele and L.J. Cooper, 2007. Lymphoid reconstruction and vaccines. Biol. Blood Marrow Transplant., 13: 17-22. http://www.ncbi.nlm.nih.gov/pubmed/17222765
71. Evans, R., J.A. Fuller, G. Christianson, D.M. Krupke and A.B. Troutt, 1997. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations. Cell Immunol., 179: 66-73. http://www.ncbi.nlm.nih.gov/pubmed/9259773
72. Weiss, J.M., J.J. Subleski, J.M. Wigginton and R.H. Wiltrout, 2007. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin. Biol. Ther., 7: 1705-1721. http://www.ncbi.nlm.nih.gov/pubmed/ 17961093
73. Passweg, J.R., U. Koehl, L. Uharek, S. Meyer-Monard and A. Tichelli, 2006. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract. Res. Clin. Haematol., 19: 811-824. http://www.ncbi.nlm.nih.gov/pubmed/16997185
74. Grzywacz, B., J.S. Miller and M.R. Verneris, 2008. Use of natural killer cells as immunotherapy for leukaemia. Best Pract. Res. Clin. Haematol., 21: 467-483. http://www.ncbi.nlm.nih.gov/pubmed/18790450